KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Guardant Health (GH) EBIAT (2017 - 2025)

Guardant Health's EBIAT history spans 9 years, with the latest figure at -$128.5 million for Q4 2025.

  • For Q4 2025, EBIAT fell 15.75% year-over-year to -$128.5 million; the TTM value through Dec 2025 reached -$416.3 million, up 4.61%, while the annual FY2025 figure was -$416.3 million, 4.61% up from the prior year.
  • EBIAT for Q4 2025 was -$128.5 million at Guardant Health, down from -$92.7 million in the prior quarter.
  • Across five years, EBIAT topped out at -$72.3 million in Q4 2021 and bottomed at -$229.4 million in Q2 2022.
  • The 5-year median for EBIAT is -$107.6 million (2021), against an average of -$118.6 million.
  • The largest annual shift saw EBIAT tumbled 237.3% in 2021 before it soared 68.28% in 2023.
  • A 5-year view of EBIAT shows it stood at -$72.3 million in 2021, then tumbled by 93.52% to -$139.9 million in 2022, then plummeted by 33.67% to -$187.0 million in 2023, then soared by 40.65% to -$111.0 million in 2024, then decreased by 15.75% to -$128.5 million in 2025.
  • Per Business Quant, the three most recent readings for GH's EBIAT are -$128.5 million (Q4 2025), -$92.7 million (Q3 2025), and -$99.9 million (Q2 2025).